SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (2108)1/29/1998 6:04:00 PM
From: Claud B  Read Replies (2) | Respond to of 7041
 
<<<If they have such a good patent protection in the making why not do good to the
investors (not the flimsy buyback, which is not working)but get real data out.>>>

Cacaito,

You're assuming that somehow the buyback was intended to support
the stock. I think your assumption is wrong. The buyback is because
the company feels it is the best investment they can make with
excess cash.

ClaudB



To: Cacaito who wrote (2108)1/29/1998 6:55:00 PM
From: Dr. Voodoo  Respond to of 7041
 
"Anyway, the more succesful phentolamine is, the more generics will go after then. But even if the generics are succesful there will be some time left for Zonagen to rise.

Someone mentioned a long while back that competitors would still have to take their formulations through clinical trials if they tried to market a rapidly absorbable phentolamine pill formulation. Does anyone know how strict the FDA is about formulations?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News